K. White

发表

Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir

Roger A. Jones, A. D. Clark, G. Wang, 2004, Nature Structural &Molecular Biology.

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Soo-Yon Rhee, Tommy F. Liu, Robert W Shafer, 2014, The Journal of antimicrobial chemotherapy.

A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents

K. White, S. Chuck, J. Pinto, 2012, The Pediatric infectious disease journal.

A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression

K. White, J. Church, S. Chuck, 2015, The Pediatric infectious disease journal.

Speaker Abstracts

K. White, D. Ward, P. Sax, 2017, Journal of the International AIDS Society.

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

K. White, J. Rockstroh, N. Clumeck, 2014, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.

K. White, C. Orkin, C. Kityo, 2021, Journal of acquired immune deficiency syndromes.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

K. White, M. Johnson, K. Squires, 2016, The lancet. HIV.

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b

K. White, M. Markowitz, H. Stellbrink, 2014, The Lancet. Infectious diseases.

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients

K. White, F. Raffi, M. Miller, 2014, Viruses.

Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131

K. White, N. Parkin, R. Mackman, 2007, Antimicrobial Agents and Chemotherapy.

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

K. White, Ross Martin, D. SenGupta, 2019, Antimicrobial Agents and Chemotherapy.

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

K. White, A. Cheng, M. Fordyce, 2014 .

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

K. White, A. Cheng, M. Fordyce, 2014, HIV clinical trials.

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naïve Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens.

K. White, D. Porter, Pamela Wong, 2017, The Journal of infectious diseases.

HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In Vitro

K. White, M. Miller, K. Andreatta, 2013, Journal of acquired immune deficiency syndromes.

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

K. White, M. Das, L. A. Burns-Naas, 2020, PloS one.

Reduced Viral Fitness and Lack of Cross-Class Resistance with Integrase Strand Transfer Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations

K. White, D. Goodman, M. Miller, 2015, Antimicrobial Agents and Chemotherapy.

Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.

K. White, Joy Y. Feng, M. Miller, 2014, Antiviral research.

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

K. White, C. Cohen, A. Cheng, 2013, HIV clinical trials.

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

K. White, J. Gallant, A. Cheng, 2017, Journal of acquired immune deficiency syndromes.

Effects of the Translocation Status of Human Immunodeﬁciency Virus Type 1 Reverse Transcriptase on the Efﬁciency of Excision of Tenofovir (cid:1)

K. White, B. Marchand, M. Götte, 2007 .

Design and Proﬁling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeﬁciency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131 (cid:1) †

K. White, N. Parkin, R. Mackman, 2008 .

Prodrug , GS-9131 Orally Bioavailable Phosphonoamidate Immunodeficiency Virus Type 1 , and Its Nucleoside-Resistant Variants of Human Nucleotide Analog Active against Design and Profiling of GS-9148 , a Novel

K. White, N. Parkin, R. Mackman, 2007 .

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

K. White, P. Sax, A. Zolopa, 2013, Journal of acquired immune deficiency syndromes.

Mechanism of Resistance to GS-9148 Conferred by the Q151L Mutation in HIV-1 Reverse Transcriptase

S. Swaminathan, K. White, S. Swaminathan, 2011, Antimicrobial Agents and Chemotherapy.

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

S. Swaminathan, K. White, A. Ray, 2005, AIDS.

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro

K. White, S. Yant, T. Cihlar, 2022, Antimicrobial agents and chemotherapy.

A Cell-Based Strategy To Assess Intrinsic Inhibition Efficiencies of HIV-1 Reverse Transcriptase Inhibitors

K. White, M. Tsiang, M. Abram, 2014, Antimicrobial Agents and Chemotherapy.

The Balance between NRTI Discrimination and Excision Drives the Susceptibility of HIV-1 RT Mutants K65R, M184V and K65R+M184V

K. White, N. Margot, M. Miller, 2007, Antiviral chemistry & chemotherapy.

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

K. White, Helen Yu, G. Kukolj, 2016, Antimicrobial Agents and Chemotherapy.

Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations

S. Swaminathan, L. Naeger, K. White, 2004, Antimicrobial Agents and Chemotherapy.

Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir

K. White, B. Marchand, M. Götte, 2007, Antimicrobial Agents and Chemotherapy.

Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

L. Naeger, K. White, T. Wrin, 2002, Antimicrobial Agents and Chemotherapy.

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

K. White, K. Borroto-Esoda, E. Svarovskaia, 2009, Retrovirology.

Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance*

Roger A. Jones, A. D. Clark, S. Tuske, 2009, The Journal of Biological Chemistry.

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

K. White, D. Porter, T. Fralich, 2015, HIV Clinical Trials.

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

K. White, J. van Lunzen, R. Ebrahimi, 2014, AIDS.

Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF in the STaR Study (GS-US-264-0110)

K. White, D. Porter, T. Fralich, 2014, Journal of acquired immune deficiency syndromes.

The Combined Anti-HIV-1 Activities of Emtricitabine and Tenofovir plus the Integrase Inhibitor Elvitegravir or Raltegravir Show High Levels of Synergy In Vitro

K. White, Rebecca M Hluhanich, M. Miller, 2014, Antimicrobial Agents and Chemotherapy.

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inf

K. White, R. Ebrahimi, P. Tebas, 2014, The Lancet. Infectious diseases.

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

B. Gazzard, K. White, J. van Lunzen, 2014, AIDS.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

K. White, J. Rockstroh, B. Kearney, 2012, The Lancet.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

K. White, P. Sax, A. Zolopa, 2012, The Lancet.

Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.

K. White, Xiaohong Liu, M. Mcgrath, 2010, Journal of molecular biology.

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

K. White, D. Porter, Pamela Wong, 2017, The Journal of infectious diseases.

The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations

S. Swaminathan, K. White, A. Ray, 2006, Antiviral therapy.

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

K. White, M. Tsiang, Gregg S. Jones, 2012, Antiviral research.

The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation

K. White, K. Borroto-Esoda, E. Svarovskaia, 2008, Journal of acquired immune deficiency syndromes.

Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations*

K. White, J. Courcambeck, N. Parkin, 2004, Journal of Biological Chemistry.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

K. White, C. Orkin, C. Cohen, 2014, AIDS patient care and STDs.

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

K. White, P. Sax, A. Zolopa, 2014, Journal of acquired immune deficiency syndromes.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

K. White, D. Ward, P. Sax, 2017, The lancet. HIV.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

K. White, H. Stellbrink, P. Sax, 2017, The Lancet.

Viral Blips were Infrequent in Treatment-Naive Adults Treated with Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF through 96 Weeks

K. White, D. Porter, W. Garner, 2017, Antiviral therapy.

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

K. White, A. Thielen, Ross Martin, 2015, Viruses.

Baseline Antiretroviral Resistance Mutations and Treatment-Emergent Resistance in HIV-1 RNA-Suppressed Patients Switching to EVG/COBI/FTC/TDF or Continuing on Their PI-, NNRTI-, or RAL-Based Regimen

K. White, H. Cao, M. Abram, 2015, Journal of acquired immune deficiency syndromes.

HIV-1 Clinical Isolates with the E138A Substitution in Reverse Transcriptase Show Full Susceptibility to Emtricitabine and Other Nucleoside Reverse Transcriptase Inhibitors

K. White, D. Porter, R. Kulkarni, 2014, Antimicrobial Agents and Chemotherapy.

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

K. White, C. Cohen, D. Wohl, 2012 .

The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

K. White, V. van Eygen, K. Babaoglu, 2012, Journal of acquired immune deficiency syndromes.

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*

K. White, F. Palella, Y. Lie, 2016, HIV clinical trials.

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

K. White, Xiaowu Chen, E. Svarovskaia, 2013, Antimicrobial Agents and Chemotherapy.

Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.

K. White, S. Yant, T. Cihlar, 2020, Journal of acquired immune deficiency syndromes.

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

K. White, B. Brenner, Devleena Shivakumar, 2021, Antimicrobial Agents and Chemotherapy.

Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.

K. White, M. Miller, R. Kulkarni, 2015, The Journal of antimicrobial chemotherapy.

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

K. White, M. Abram, N. Margot, 2019, Journal of medical virology.

HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil

M. Lederman, D. Kuritzkes, K. White, 2013, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.

M. Wulfsohn, K. White, Lijie Zhong, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mutations in the thumb–connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients

K. White, K. Borroto-Esoda, E. Svarovskaia, 2009, Antiviral therapy.

Inhibition of 2′,5′-Oligoadenylate Synthetase Expression and Function by the Human Cytomegalovirus ORF94 Gene Product

K. White, E. Mocarski, S. Avdic, 2011, Journal of Virology.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

K. White, Ross Martin, Hal Martin, 2021, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.

K. White, Ross Martin, Hal Martin, 2020, Journal of acquired immune deficiency syndromes.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

K. White, M. Abram, N. Margot, 2017, PloS one.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

K. White, Ross Martin, E. Quirk, 2019, The Journal of antimicrobial chemotherapy.

Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions

K. White, M. Miller, K. Andreatta, 2015, Antimicrobial Agents and Chemotherapy.

Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials

K. White, P. Sax, M. Das, 2018, Antiviral therapy.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)

K. White, H. Cao, S. Hodder, 2017, HIV clinical trials.

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.

K. White, A. Thielen, Ross Martin, 2018, Journal of acquired immune deficiency syndromes.

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.

K. White, D. Brainard, Ross Martin, 2021, The Journal of antimicrobial chemotherapy.

1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance

K. White, S. Yant, T. Cihlar, 2020 .

Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels

K. White, G. Stepan, S. Yant, 2016 .

A Cell-Based Strategy To Assess Intrinsic Inhibition Efficiencies of HIV-1 Reverse Transcriptase Inhibitors

K. White, M. Tsiang, M. Abram, 2014, Antimicrobial Agents and Chemotherapy.

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

K. White, M. Tsiang, Gregg S. Jones, 2012, Antiviral research.